Regencell Bioscience
- Market cap
- 3.53B
- P/E (TTM)i
- -296.25
- P/Bi
- 263.33
- EPSi
- -0.02
- Div yieldi
- 0.00%
- 52W posi
- 4%
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions decreased by 4 in the most recent period (2026/Q3).
- Total institutional ownership (as a % of shares) was little changed.
Institutional ownership
- Held by institutions
- 0.35% 0.00pp
- Institutions
- 39 -4
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Top holders as of 2026-03-18
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
8 filings tracked · 0 buys · 2 sells
| Name | Role | Stake |
|---|---|---|
| Yat-Gai Au | Chairperson & CEO | 88.38% |
| Hoor Han Lo | Independent Director | 0.12% |
| Yat-Pui Au | Chief Business Officer | 0.12% |
| Wing Yan Lo | Independent Director | -- |
| Yee Wah Hui | Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-05-26 | Wing Yan Lo | Independent Director | Derivative Sale to Issuer | -70,600 | -- |
| 2026-05-26 | Yee Wah Hui | Independent Director | Derivative Sale to Issuer | -19,000 | -- |
| 2026-03-17 | Yat-Gai Au | Chairperson & CEO | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Wing Yan Lo | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Yee Wah Hui | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Yat-Pui Au | Chief Business Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Hoor Han Lo | Independent Director | Initial Statement of Beneficial | 0 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 05:07:29 · For reference only, not investment advice and not tailored to your situation.